For years, scientists knew that blood vessels could receive a chemical signal from the thin layer of cells lining their inner surface. The problem was simple to state but surprisingly difficult to solve:
What was the mysterious substance responsible for telling blood vessels to relax?
Researchers gave the unknown substance a name: endothelium-derived relaxing factor, or EDRF.
The name described what scientists knew about it without revealing what it actually was. It came from the endothelium, the cellular lining of blood vessels, and it caused the surrounding vascular muscle to relax. Beyond that, its identity remained elusive.
Then, in 1987, a series of pivotal experiments changed the story.
Researchers showed that EDRF had the properties of nitric oxide (NO) and that the amino acid L-arginine could serve as the source of nitric oxide production in the vascular system.
That breakthrough transformed a mysterious physiological signal into a recognizable chemical pathway.
The EDRF discovery of 1987 involving arginine and nitric oxide is therefore more than a technical footnote in cardiovascular research history. It is a classic example of how scientists can spend years chasing an unknown biological messenger before realizing that the answer is a remarkably small and familiar molecule.
This article explains what EDRF was, why identifying it was so difficult, how nitric oxide entered the picture, what arginine had to do with the discovery, and why the 1987 breakthrough remains an important moment in the history of vascular biology.
What Was EDRF?
Endothelium-derived relaxing factor, or EDRF, was the name given to an unidentified substance released by endothelial cells that caused nearby vascular smooth muscle to relax.
The endothelium is the extremely thin layer of cells lining the inside of blood vessels. Although it looks simple, this cellular layer is chemically active. It communicates with the tissues around it and helps regulate how blood vessels respond to different signals.
The mystery became apparent when researchers began studying what happened when blood vessels were exposed to particular chemical stimuli.
Under the right experimental conditions, an intact endothelium could trigger relaxation of the underlying vascular smooth muscle. Remove or damage the endothelial layer, however, and that response could disappear.
Something produced by the endothelium was clearly responsible.
Scientists initially didn't know its chemical identity.
So they called it EDRF.
The term itself is important because it captures the state of knowledge at the time. Researchers weren't saying, "We have discovered nitric oxide."
They were saying, essentially:
There is a relaxing factor. It comes from the endothelium. We don't yet know exactly what it is.
That distinction is central to understanding the EDRF story.
Why Was the Identity of EDRF Such a Difficult Mystery?
At first glance, identifying a molecule that relaxes blood vessels might sound straightforward. In practice, it was anything but.
The researchers were dealing with a substance that was biologically active at extremely low concentrations and could be difficult to isolate and characterize.
There was another problem: EDRF did not necessarily behave like a conventional, stable hormone.
Instead, the factor appeared to act locally and rapidly.
It could be generated by endothelial cells, move a very short distance to neighboring vascular smooth muscle cells, and trigger a response.
That created a challenging experimental puzzle.
Scientists had to determine:
- What produced EDRF?
- What chemical structure did it have?
- How stable was it?
- How did it move between cells?
- What happened after it reached vascular smooth muscle?
- Was EDRF one molecule or several related substances?
- Could a known chemical reproduce its effects?
Each answer narrowed the possibilities, but none immediately revealed the identity of the mysterious factor.
The Endothelium Was the Clue
One of the most important observations was that the endothelial lining itself mattered.
Researchers studying isolated blood vessel preparations found that certain substances could cause relaxation when the endothelium was present but not when it had been removed.
That suggested the stimulus wasn't simply acting directly on the vascular muscle.
Instead, the endothelial cells were responding to the stimulus and releasing a secondary signal.
That secondary signal was EDRF.
The idea was conceptually powerful.
The endothelium wasn't merely an inert inner coating. It was acting as a signaling interface between the contents of a blood vessel and the surrounding vascular tissue.
The mystery was figuring out the identity of the messenger.
The EDRF Story Begins Before 1987
Although 1987 is the key year in the EDRF mystery, the discovery did not happen overnight.
The scientific groundwork stretched back years.
A landmark step came in 1980, when Robert Furchgott and John Zawadzki reported experiments showing that the relaxation response of blood vessels could depend on the presence of an intact endothelial layer.
This work helped establish the concept that endothelial cells could release a relaxing substance.
That substance became known as endothelium-derived relaxing factor.
The terminology stuck because the identity of the factor remained uncertain.
Throughout the following years, researchers tried to characterize EDRF and determine whether it might be a previously known compound or an entirely new type of biological messenger.
This created one of those unusual scientific situations in which researchers could observe the effects of something long before they knew what the thing actually was.
They could measure blood vessel relaxation.
They could investigate the conditions that caused it.
They could study its stability.
But the molecular identity remained frustratingly out of reach.
The Strange Clues Pointing Toward Nitric Oxide
One reason the EDRF mystery eventually became solvable was that researchers began noticing similarities between EDRF and nitric oxide.
Nitric oxide was already known to chemistry and physiology. It was a small, simple molecule containing one nitrogen atom and one oxygen atom.
The idea that such a small molecule could function as a biological messenger was not immediately obvious.
Yet several observations began to line up.
EDRF had a very short-lived biological effect.
Nitric oxide was also highly reactive and short-lived in biological environments.
EDRF could cause vascular smooth muscle relaxation.
Nitric oxide was known to have vasorelaxant properties.
Certain compounds that affected nitric oxide also affected responses attributed to EDRF.
The similarities became increasingly difficult to ignore.
But correlation wasn't enough.
To solve the mystery, researchers needed stronger evidence.
They needed to demonstrate that the supposedly mysterious EDRF and nitric oxide behaved sufficiently similarly that they were effectively the same signaling substance.
EDRF Identified as Nitric Oxide
In 1987, several research groups published findings that brought the mystery to a decisive point.
One of the most influential lines of work came from Louis Ignarro and colleagues, who compared the properties of EDRF with those of nitric oxide.
Another crucial contribution came from Salvador Moncada, Richard Palmer and colleagues, whose work helped establish the relationship between endothelial relaxing activity and nitric oxide.
The findings converged on a remarkable conclusion:
EDRF was nitric oxide, or a substance with the chemical and biological identity of nitric oxide.
This was the breakthrough researchers had been pursuing for years.
The mysterious endothelial messenger now had a molecular identity.
The phrase "endothelium-derived relaxing factor" could finally be translated into a specific chemical answer:
Nitric oxide.
The EDRF nitric oxide discovery of 1987 fundamentally changed how scientists understood signaling in blood vessels.
But there was still another part of the story.
Where did the nitric oxide come from?
The Arginine Connection
The answer involved an amino acid called L-arginine.
Research demonstrated that endothelial cells could produce nitric oxide from L-arginine through an enzymatic process.
This was a major conceptual advance.
The mystery was no longer simply:
What is EDRF?
It became:
How do endothelial cells convert an ordinary biological molecule into nitric oxide, and how does that nitric oxide tell neighboring cells to relax?
This connected the 1987 EDRF discovery to a broader signaling pathway.
The simplified version is:
L-arginine → nitric oxide → vascular smooth muscle signaling → relaxation
The actual biology is more detailed, but this sequence captures the essential discovery.
L-arginine wasn't simply an ingredient that happened to appear in the experiments. It was identified as the substrate from which nitric oxide could be generated by nitric oxide synthase enzymes.
That made the finding particularly significant.
Scientists had identified both the messenger and an important source of the atoms used to make that messenger.
How Is Nitric Oxide Made From Arginine?
The enzyme family responsible for nitric oxide production is known as nitric oxide synthase, commonly abbreviated as NOS.
Nitric oxide synthase catalyzes the conversion of L-arginine into nitric oxide and another amino acid-derived product, L-citrulline.
At a simplified level:
L-arginine is the substrate.
Nitric oxide synthase is the enzyme.
Nitric oxide is the signaling molecule produced.
The chemistry is more complicated than that three-part description suggests, because the enzyme requires several cofactors and participates in an oxygen-dependent reaction.
For understanding the historical EDRF discovery, however, the central point is straightforward:
Researchers discovered that endothelial nitric oxide production could be traced back to L-arginine.
That was the arginine-derived signaling discovery that helped connect a mysterious physiological effect to a defined biochemical pathway.
Why the Arginine Finding Mattered
The identification of nitric oxide as EDRF solved one mystery.
The connection to arginine helped explain another.
Before this work, it was possible to observe endothelial relaxation as a physiological phenomenon without understanding how the endothelial cell generated the signal.
Once L-arginine was identified as the precursor, scientists could begin asking much more precise biochemical questions.
For example:
- Which enzyme converts arginine into nitric oxide?
- Where inside the cell does this occur?
- What controls the enzyme's activity?
- Which signals stimulate nitric oxide production?
- How does nitric oxide move to nearby cells?
- What happens after nitric oxide reaches vascular smooth muscle?
- How is the signal terminated?
These questions transformed the field.
The mystery had become a pathway.
And pathways can be investigated systematically.
How Does Nitric Oxide Relax Blood Vessels?
The simplest answer is that nitric oxide acts as a short-range signaling molecule that activates a pathway inside vascular smooth muscle cells, ultimately promoting relaxation.
A key component of this pathway is an enzyme called soluble guanylyl cyclase.
When nitric oxide reaches vascular smooth muscle, it can activate soluble guanylyl cyclase.
This increases the intracellular signaling molecule cyclic guanosine monophosphate, or cGMP.
The resulting signaling changes favor relaxation of the smooth muscle.
In simplified form:
Endothelial cell
↓
L-arginine
↓
Nitric oxide synthase
↓
Nitric oxide
↓
Vascular smooth muscle
↓
Soluble guanylyl cyclase
↓
cGMP
↓
Smooth muscle relaxation
This pathway helps explain why identifying EDRF was so important.
Scientists weren't merely naming an unknown substance.
They were uncovering a communication system between two different cell types.
A Practical Example of the Signaling Process
Imagine a small blood vessel in an experimental laboratory preparation.
Researchers apply a stimulus that activates the endothelial cells lining the vessel.
The endothelial cells respond by increasing nitric oxide production.
Nitric oxide is then released and diffuses into the adjacent vascular smooth muscle.
Inside those muscle cells, nitric oxide activates soluble guanylyl cyclase.
cGMP levels rise.
The smooth muscle relaxes.
The vessel's diameter increases.
That sequence converts an external stimulus into a measurable mechanical response.
Before the EDRF mystery was solved, researchers could observe the final step while having only an incomplete picture of the chemical events in between.
The 1987 work helped fill in that missing middle.
Why Nitric Oxide Was Such a Surprising Answer
Part of what makes the EDRF discovery so memorable is the simplicity of the molecule involved.
Nitric oxide is tiny.
It isn't a large protein or complex hormone.
It is a simple gaseous molecule that can be produced by cells and used as a local signaling messenger.
That challenged conventional expectations about what a biological signaling molecule could look like.
A molecule did not need to be large, stable, or transported through the body like a traditional circulating messenger to have a powerful biological effect.
Nitric oxide could be produced on demand, act locally, and disappear quickly.
Those characteristics made it particularly well suited to short-range signaling.
The very properties that made nitric oxide difficult to identify also helped explain why it had been difficult to study.
Why Was EDRF So Hard to Isolate?
The short-lived nature of nitric oxide helps explain the historical challenge.
If a signaling molecule is stable, researchers can potentially collect it, purify it, and analyze its chemical structure.
Nitric oxide doesn't behave that way in biological environments.
It is reactive.
Its lifetime can be very short.
Its concentration can be extremely low.
And its effects depend on the surrounding chemical environment.
That meant traditional approaches to identifying a stable biological compound were not necessarily ideal.
Instead, researchers had to combine physiological experiments, pharmacological observations, chemical comparisons, biochemical studies, and increasingly sophisticated analytical methods.
The solution emerged from convergence rather than from one simple experiment.
What Did the 1987 Breakthrough Actually Prove?
It's worth being precise about the historical significance.
The 1987 research did not represent a single experiment performed by one scientist that instantly solved every aspect of the EDRF mystery.
Rather, several complementary findings converged around the same explanation.
Researchers compared EDRF with nitric oxide and found striking similarities in their biological and chemical behavior.
They also demonstrated relationships between endothelial nitric oxide production and L-arginine.
Together, these results established a compelling molecular explanation for the relaxing factor.
This is an important lesson in how scientific discoveries actually happen.
Breakthroughs are often described with a single year because that makes the history easier to remember. In reality, the evidence usually accumulates across multiple laboratories, experiments, and publications.
The year 1987 represents the point at which the EDRF mystery moved decisively from uncertainty toward identification.
The Endothelium Was Revealed as a Signaling Organ
One of the biggest conceptual consequences of the discovery was a change in how scientists viewed the endothelium.
The endothelial lining of a blood vessel had once been easy to imagine as a passive barrier.
The EDRF story demonstrated something far more interesting.
Endothelial cells could sense signals and communicate with neighboring cells by releasing biologically active molecules.
Nitric oxide became one of the clearest examples of this principle.
The endothelium was not simply separating blood from vascular tissue.
It was participating actively in vascular regulation.
That insight opened the door to an enormous amount of subsequent research into endothelial signaling.
From an Unknown Factor to a Research Field
Once EDRF was identified as nitric oxide, scientists could stop asking what the substance was and start exploring what nitric oxide did.
That distinction matters.
Identifying a molecule is often the beginning of a scientific field rather than the end of one.
The discovery prompted research into:
- nitric oxide synthase enzymes
- L-arginine metabolism
- cGMP signaling
- endothelial cell communication
- vascular smooth muscle responses
- short-range cellular signaling
- nitric oxide production and breakdown
- interactions between nitric oxide and other signaling molecules
The field expanded far beyond the original observation of blood vessel relaxation.
A molecule that initially appeared to be a specialized vascular messenger became recognized as a versatile signaling molecule with roles across biological systems.
Why the EDRF Discovery Changed Cardiovascular Research History
The phrase "cardiovascular research breakthrough" can describe many different discoveries, but the EDRF story has a distinctive place in that history.
It connected several levels of biology.
At the cellular level, endothelial cells produced a signal.
At the chemical level, that signal was nitric oxide.
At the metabolic level, L-arginine served as a precursor.
At the intracellular level, nitric oxide activated soluble guanylyl cyclase and increased cGMP.
At the tissue level, vascular smooth muscle relaxed.
At the systems level, the ability of blood vessels to change their diameter could therefore be understood as an actively regulated signaling process.
That chain of reasoning is what made the discovery so powerful.
It wasn't merely:
"EDRF is nitric oxide."
It was:
"Here is how one cell produces a small signaling molecule, how that molecule communicates with another cell, and how the signal produces a measurable change in vascular behavior."
The Scientists Behind the Discovery
Several researchers played central roles in the scientific journey from EDRF to nitric oxide.
Robert Furchgott
Robert Furchgott's work was fundamental to establishing the importance of the endothelium in vascular relaxation.
His experiments with John Zawadzki in 1980 demonstrated that the presence of endothelial cells was essential for certain relaxation responses.
This provided the foundation for the EDRF concept.
Furchgott later shared the 1998 Nobel Prize in Physiology or Medicine for discoveries concerning nitric oxide as a signaling molecule.
Louis Ignarro
Louis Ignarro and his colleagues were among the researchers who helped establish the connection between EDRF and nitric oxide in 1987.
Their work provided important evidence that the mysterious endothelial relaxing factor had properties consistent with nitric oxide.
Ignarro also later shared the 1998 Nobel Prize in Physiology or Medicine with Furchgott and Ferid Murad.
Salvador Moncada and Richard Palmer
Salvador Moncada and Richard Palmer were also central figures in the work connecting endothelial relaxation with nitric oxide.
Their research helped demonstrate that endothelial cells could generate nitric oxide from L-arginine.
This linked the physiological phenomenon to a biochemical source.
Ferid Murad
Ferid Murad had previously contributed important research showing that nitric oxide-related compounds could activate soluble guanylyl cyclase and increase cGMP.
His work helped establish the intracellular signaling mechanism through which nitric oxide could produce smooth muscle relaxation.
Together, these lines of research created a much clearer picture of nitric oxide signaling.
The 1998 Nobel Prize Confirmed the Broader Importance
The importance of this scientific story was formally recognized in 1998.
Robert Furchgott, Louis Ignarro, and Ferid Murad received the Nobel Prize in Physiology or Medicine for their discoveries concerning nitric oxide as a signaling molecule in the cardiovascular system.
The prize came more than a decade after the crucial 1987 EDRF findings.
That timeline is revealing.
A discovery can be immediately important without its full significance being understood immediately.
The 1987 work helped identify the mysterious factor.
The years that followed demonstrated just how broadly important nitric oxide signaling was.
EDRF Discovery 1987 Arginine Nitric Oxide: The Timeline
For readers looking for the shortest version of the story, the timeline looks like this:
1980: The endothelial clue
Experiments by Furchgott and Zawadzki showed that an intact endothelium was necessary for certain vascular relaxation responses.
The concept of an endothelium-derived relaxing factor emerged.
Early 1980s: The mystery deepens
Researchers investigated the properties, stability, and biological behavior of EDRF.
Its identity remained uncertain.
Mid-1980s: Nitric oxide becomes a serious candidate
Researchers increasingly noticed similarities between nitric oxide and EDRF, including their effects on vascular smooth muscle and their short-lived behavior.
1987: The breakthrough
Major studies provided compelling evidence that EDRF was nitric oxide and that endothelial nitric oxide production was connected to L-arginine.
The mystery had a molecular answer.
1998: Nobel recognition
Furchgott, Ignarro, and Murad received the Nobel Prize for discoveries concerning nitric oxide as a signaling molecule.
This placed the work in the broader history of modern cell signaling and cardiovascular research.
What Is the Difference Between EDRF and Nitric Oxide?
This question often causes confusion.
EDRF was the name for the unidentified biological activity or relaxing factor. Nitric oxide is the molecular identity ultimately associated with that activity.
In other words, EDRF was a descriptive term created before the chemical identity was known.
Think of it like discovering an unknown substance in a laboratory and temporarily labeling it "Compound X."
Once the compound is identified, the temporary name becomes less useful.
EDRF was the biological mystery.
Nitric oxide was the answer.
Was Nitric Oxide Really Made From Arginine?
Yes.
Research established that endothelial nitric oxide production uses L-arginine as a substrate.
Nitric oxide synthase enzymes catalyze the reaction, producing nitric oxide and L-citrulline.
That discovery was particularly important because it connected a recognizable metabolic molecule with a gaseous signaling messenger.
It also provided researchers with a biochemical framework for studying how nitric oxide production could be regulated.
The discovery should not be interpreted as meaning that simply consuming more arginine automatically produces a predictable increase in nitric oxide signaling throughout the body. Biological regulation is considerably more complicated than a single-substrate model.
The historical point is narrower and more precise:
L-arginine was identified as the substrate used by nitric oxide synthase in the enzymatic production of nitric oxide.
Why This Discovery Still Matters Today
The EDRF mystery may sound like an old chapter in a textbook, but the scientific principle behind it remains relevant.
Modern biology depends heavily on understanding cell-to-cell signaling.
Cells constantly release molecules that influence nearby cells.
Some signals are proteins.
Others are lipids.
Some are ions.
And some, like nitric oxide, are very small molecules.
The EDRF story is a particularly elegant example because researchers first observed a biological effect and only later discovered the messenger responsible.
That pattern appears throughout science.
A phenomenon can be measurable long before its molecular mechanism is understood.
What Can This Discovery Teach Us About Scientific Research?
The EDRF story offers several broader lessons.
1. A mystery can be useful
Giving the unknown substance the name EDRF allowed researchers to talk about and study the phenomenon even before they knew its identity.
A temporary label isn't a failure.
It can be a tool for organizing research.
2. Multiple clues can converge
No single observation necessarily solved the mystery.
Instead, researchers accumulated evidence about biological activity, chemical behavior, endothelial dependence, nitric oxide, and arginine.
The solution emerged when those observations pointed toward the same explanation.
3. Simple molecules can have sophisticated biological roles
Nitric oxide is chemically simple, but its biological signaling role is remarkably sophisticated.
Molecular complexity and biological importance are not the same thing.
4. Discovery often creates more questions
Identifying EDRF as nitric oxide answered one question while opening many others.
Scientists could then investigate nitric oxide synthase, cGMP signaling, regulation, cellular localization, and other aspects of the pathway.
A solved mystery can become the starting point for an entire research field.
A Simple Way to Remember the EDRF Discovery
If you're studying the history of cardiovascular research, remember the discovery as a four-step chain:
Endothelium → EDRF → nitric oxide → arginine
The endothelium was observed to release a relaxing factor.
That factor was called EDRF.
In 1987, evidence established that EDRF was nitric oxide.
Researchers also connected nitric oxide production to L-arginine.
From there, the signaling pathway became increasingly clear.
That sequence is much easier to remember than a collection of disconnected dates and names.
Common Misconceptions About the 1987 Discovery
"EDRF and nitric oxide were two different substances."
Not in the sense implied by the historical mystery.
EDRF was the name given to the unidentified endothelium-derived relaxing activity. Research in 1987 established that nitric oxide accounted for that activity.
"Scientists discovered nitric oxide in 1987."
Not exactly.
Nitric oxide was already known as a chemical compound.
What changed in 1987 was the understanding that nitric oxide could function as an important biological signaling molecule and that it accounted for EDRF activity.
"Arginine itself was the relaxing factor."
No.
L-arginine was identified as a substrate used in the enzymatic production of nitric oxide.
The signaling molecule associated with EDRF was nitric oxide.
"One experiment solved the entire mystery."
The history is more nuanced.
The 1987 breakthrough resulted from converging evidence from multiple researchers and experimental approaches.
Science rarely advances as cleanly as a single before-and-after moment suggests.
Why This Is a Fascinating Example of Molecular Signaling
The EDRF discovery is compelling because it connects an observable physical event to an invisible molecular process.
Researchers could watch a blood vessel relax.
They couldn't initially see the messenger responsible.
Eventually, they traced the response back to a molecule small enough to evade the assumptions scientists might have made about conventional biological messengers.
That is what makes the story memorable.
The mystery wasn't solved by finding a giant hidden structure.
It was solved by recognizing that an exceptionally small molecule could carry an exceptionally important message.
How the Discovery Connects to Plant-Based and Mindful Living
The history of nitric oxide is fundamentally a story about biology, chemistry, and scientific curiosity. It also provides an interesting reminder that nutrition and physiology cannot be reduced to simplistic claims about individual foods or nutrients.
L-arginine occurs naturally in many foods, including plant foods, but the body's signaling systems are regulated networks rather than simple input-output machines.
For people interested in plant-based living, the more useful lesson is to appreciate the complexity of human biology rather than turning one molecule into a nutritional shortcut.
That spirit of curiosity fits naturally with mindful living: understand the science, distinguish established findings from speculation, and avoid assuming that one biological pathway tells the whole story.
For those who like expressing their values through everyday clothing, The Dharma Store offers plant-focused designs, including Vegan T-Shirts, inspired by compassion and ethical living.
What the EDRF Mystery Ultimately Revealed
The question that began this scientific story was deceptively simple:
What causes blood vessels to relax when the endothelium is present?
The answer took years to emerge.
Researchers first established that the endothelium was essential to the response.
They then characterized the mysterious EDRF.
Scientists eventually recognized striking similarities between EDRF and nitric oxide.
In 1987, the evidence converged strongly enough to identify EDRF with nitric oxide.
Research also showed that endothelial nitric oxide production could be derived from L-arginine through nitric oxide synthase.
That turned an unexplained physiological observation into a defined molecular signaling pathway.
The story can therefore be expressed in one sentence:
The 1987 EDRF discovery revealed that the mysterious endothelium-derived relaxing factor was nitric oxide, produced from L-arginine through nitric oxide synthase and used as a local signal to promote vascular smooth muscle relaxation.
That is why the discovery remains such an important chapter in cardiovascular research history.
FAQ: EDRF, Nitric Oxide, and Arginine
What was EDRF?
EDRF stands for endothelium-derived relaxing factor. It was the name researchers gave to an unidentified substance released by endothelial cells that caused nearby vascular smooth muscle to relax. Research eventually identified the factor as nitric oxide.
When was EDRF identified as nitric oxide?
The critical identification occurred in 1987, when research from multiple groups provided strong evidence that EDRF and nitric oxide were essentially the same biological signaling activity.
How is nitric oxide made from arginine?
Nitric oxide is produced from L-arginine by enzymes called nitric oxide synthases. The reaction produces nitric oxide and L-citrulline and requires several cofactors.
How does nitric oxide relax blood vessels?
Nitric oxide diffuses into nearby vascular smooth muscle cells and activates soluble guanylyl cyclase. This increases cGMP, a cellular signaling molecule that promotes smooth muscle relaxation.
Why was the EDRF discovery important?
The discovery demonstrated that a very small molecule could act as a powerful biological messenger between cells. It also revealed that endothelial cells actively regulate vascular behavior through chemical signaling.
Who discovered that EDRF was nitric oxide?
The identification was established through complementary research involving several scientists, particularly Louis Ignarro and colleagues and Salvador Moncada, Richard Palmer, and colleagues. Earlier work by Robert Furchgott and John Zawadzki established the crucial role of the endothelium in the relaxation response.
The Lasting Significance of the 1987 EDRF Discovery
The EDRF story is a reminder that some of science's most important discoveries begin with an unanswered question.
Researchers knew the endothelium could somehow tell vascular smooth muscle to relax. They could observe the response, measure it, and investigate its characteristics. But for years, the actual messenger remained hidden behind the temporary name EDRF.
The breakthrough came when researchers connected the mysterious factor to nitric oxide.
Then came the arginine connection.
Then came a deeper understanding of nitric oxide synthase and cGMP signaling.
What had started as an unexplained effect became a coherent molecular pathway.
The EDRF discovery of 1987 involving arginine and nitric oxide therefore stands as a particularly satisfying example of a scientific mystery solved: a phenomenon first described by what it did was eventually identified by what it was.
And the answer was unexpectedly small.
A molecule consisting of just nitrogen and oxygen had been carrying a major biological message all along.
The information in this article is for educational purposes only and should not be considered medical advice. Always consult a qualified healthcare professional regarding dietary or health concerns.